Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403341 | 1.00 | HCAR2 (0.67) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL2890671 | 1.00 | HCAR2 (0.67) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL3800597 | 0.98 | HCAR2 (0.64) | HCAR2ATMTSHRTP53EGLN1 | |
| Ammonia Solution, Strong SCHEMBL27753065 | 0.98 | HCAR2 (0.64) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL8901889 | 0.94 | HCAR2 (0.60) | HCAR2ATMTSHRTP53SMN1; SMN2 | |
| SCHEMBL30298850 | 0.94 | HCAR2 (0.60) | HCAR2ATMTSHRTP53SMN1; SMN2 | |
| SCHEMBL19048762 | 0.94 | HCAR2 (0.60) | HCAR2ATMTSHRTP53SMN1; SMN2 | |
| SCHEMBL1264625 | 0.94 | HCAR2 (0.60) | HCAR2ATMTSHRTP53SMN1; SMN2 | |
| SCHEMBL1264623 | 0.94 | HCAR2 (0.60) | HCAR2ATMTSHRTP53SMN1; SMN2 | |
| SCHEMBL403340 | 0.91 | ATM (0.56) | HCAR2ATMTSHRTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0140530-B1 | LATENTLY-CURABLE ORGANOSILICONE RELEASE COATING COMPOSITION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-03-08 | — | — | EP | claimed |
| EP-0140530-A1 | Latently-curable organosilicone release coating composition | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-05-08 | — | — | EP | claimed |
| US-4504645-A | GELATION INHIBITION USING A MONOESTER OR -AMIDE OF AN UNSATURATED DICARBOXYLIC ACID; SHELF LIFE; HEAT CURING | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-03-12 | — | — | US | claimed |
| US-8101701-B2 | having a hydrophilic group and a silicon-containing alkyl group within molecule; lenses with high oxygen permeability independent from the water content may be obtained, wherein the fumaric acid derivatives is superior in compatibility with the hydrophilic monomer used in combination | MENICON NECT CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-1930338-A1 | Fumaric acid derivates and ophtalmic lenses using the same | E-brain Corporation Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | MENICON NECT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-4439517-A | Process for the formation of images with epoxide resin | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4393180-A | Curing agents for epoxide resins and compositions containing them | CIBA-GEIGY CORPORATION (US) | 1983-07-12 | — | — | US | disclosed |
| US-4130511-A | AROMATIC COMPOUND, INORGANIC NITRATE | CIBA-GEIGY CORPORATION (US) | 1978-12-19 | — | — | US | disclosed |
| US-4115296-A | Polyhalocarboxylic acid salts as accelerators for curing epoxide resins | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4101459-A | TRIFLUOROMETHANESULFONIC ACID SALTS | CIBA-GEIGY CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | FAH, FH, AQP4 | HCAR2 83/4885ATM 1427/4885TSHR 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.